Errant Gene Therapeutics, LLC (“EGT”), Files Patent Infringement Complaint Against Defendant Bluebird Bio

Errant Gene Therapeutics, LLC (“EGT”), Files Patent Infringement Complaint Against Defendant Bluebird Bio

The conflicts between biotech venture Errant Gene Therapeutics LLC (“EGT”) and publicly traded Bluebird Bio continue as the former now alleges the latter committed patent infringement. TrialSite first reported tensions between these two gene therapy ventures in “A Familyman’s Battle against the Forefront of Capitalist Medicine: The Case of Errant Gene Therapeutics.” Both are companies that work to develop transformative gene therapies for patients with genetic and orphan diseases.  

Filed on October 21, 2021, in Delaware, the EGT complaint states that Bluebird submitted its Biologics License Application (“BLA”) to the FDA for its Infringing Drug Product in September of 2021. Bluebird’s betibeglogene autotemcel (beti-cel) drug product (marketed as ZYNTEGLO® and LENTIGLOBIN®) uses the BB305 lentiviral vector. The complaint states that Bluebird has engaged and continues to engage in non-regulatory conduct and post-FDA submission activities related to the commercialization of the BB305 Vector, which infringes on EGT’s exclusive worldwide patented rights to patents.  

EGT founder, Pat Girondi, insists that EGT’s goal is to make safe gene therapy accessible for all patients. Mr. Girondi, formerly a commodities broker in Chicago, became a biotech entrepreneur out of necessity to save his son, who struggles with Thalassemia. EGT’s gene therapy product is projected to cost well over 1 million dollars less — per patient than Bluebird’s Infringing Drug Product. TrialSite found the action via Case 1:21-cv-01478-UNA.